CureVac (NASDAQ:CVAC) | WebDisclosure

Basculer en Français

8305	Companies
115226	Keywords
55530	Articles
62575	Press releases

Home
Companies
CureVac

BRIEF

published on 04/18/2024 at 13:05, 7 months 3 days ago

CureVac annoncera ses résultats du quatrième trimestre et de l'année 2023 le 24 avril 2024

Résultats Financiers Conférence Téléphonique CureVac Technologies ARNm Mises À Jour Commerciales
BRIEF

published on 04/18/2024 at 13:05, 7 months 3 days ago

CureVac to Announce Q4 and Full-Year 2023 Results on April 24, 2024

Financial Results Conference Call CureVac MRNA Technologies Business Updates
PRESS RELEASE

published on 04/18/2024 at 13:00, 7 months 3 days ago

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
CureVac to report Q4 and full-year 2023 financial results and business update on April 24, 2024. Conference call and webcast scheduled. Details at www.curevac.com/en/newsroom/events/

Financial Results Conference Call Business Update MRNA Technology CureVac
BRIEF

published on 04/16/2024 at 13:05, 7 months 5 days ago

CureVac et MD Anderson collaborent sur des vaccins innovants contre le cancer

Technologie ARNm CureVac MD Anderson Vaccins Contre Le Cancer Collaboration Biopharmaceutique
BRIEF

published on 04/16/2024 at 13:05, 7 months 5 days ago

CureVac and MD Anderson Collaborate on Innovative Cancer Vaccines

MRNA Technology CureVac MD Anderson Cancer Vaccines Biopharmaceutical Collaboration
PRESS RELEASE

published on 04/16/2024 at 13:00, 7 months 5 days ago

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
CureVac and MD Anderson announce strategic collaboration to develop mRNA-based cancer vaccines, leveraging respective expertise to address unmet medical needs in hematological and solid tumors

Clinical Research Collaboration CureVac MD Anderson MRNA-based Cancer Vaccines
BRIEF

published on 04/04/2024 at 13:05, 7 months 17 days ago

CureVac annonce des résultats positifs de phase 2 pour son vaccin contre la grippe en collaboration avec GSK

GSK Technologie ARNm CureVac Vaccin Contre La Grippe Essai De Phase 2
BRIEF

published on 04/04/2024 at 13:05, 7 months 17 days ago

CureVac Reports Positive Phase 2 Results for Influenza Vaccine in Collaboration with GSK

GSK MRNA Technology CureVac Influenza Vaccine Phase 2 Trial
PRESS RELEASE

published on 04/04/2024 at 13:00, 7 months 17 days ago

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
CureVac announces positive Phase 2 interim results for seasonal influenza vaccine in collaboration with GSK, showing strong antibody titers and safety profile

GSK CureVac Phase 2 Seasonal Influenza Vaccine MRNA
PRESS RELEASE

published on 11/01/2023 at 13:00, 1 year ago

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

Accesswire

Published on 11/22/2024 at 09:00, 3 hours 49 minutes ago

Industrial Software Company mlean Celebrates 10 Years of Continuous Improvement
Published on 11/22/2024 at 00:00, 12 hours 49 minutes ago

Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 14 hours 44 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 14 hours 59 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 16 hours 34 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals

View all ACCESSWIRE

EQS Group

Published on 11/22/2024 at 11:54, 54 minutes ago

PIERER Mobility denies media reports about Mark Mateschitz's participation in PIERER Mobility and KTM
Published on 11/22/2024 at 11:45, 1 hour 4 minutes ago

How 5G Transforms Life: A Foreigner's Journey Through East China's Digital Revolution
Published on 11/22/2024 at 11:21, 1 hour 28 minutes ago

Original-Research: ParTec AG (von First Berlin Equity Research GmbH): Buy
Published on 11/22/2024 at 11:06, 1 hour 43 minutes ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
Published on 11/22/2024 at 11:00, 1 hour 49 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 1 day 5 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 5 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 5 hours ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 1 day 16 hours ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 1 day 17 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE